LucidQuest’s Post

Thoughts on this? >> US spent $3B on DMD treatments as confirmatory studies still underway, JAMA paper says >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #healthcare #pharmaceutical #pharma

https://lnkd.in/eQaiFzEw Key Insights: • The Efemoral Vascular Scaffold System (EVSS) introduces a novel approach to treating peripheral arterial occlusive disease (PAOD) by addressing specific anatomical challenges and complex biomechanics of patients with athero-occlusive disease in the leg Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #medicaldevices #breakthrough #devicedesignation #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Ginsenoside Rg5 as an anticancer drug: a comprehensive review on mechanisms, structure–activity relationship, and prospects for clinical advancement.  Our latest  article published in “Pharmacological Report”   is now available online @ https://lnkd.in/ebyfAura  

Therapy Watch #Rheumatology market snapshot. Offering an introduction to the real-world patient data collected by our #TherapyWatch study. In this snapshot, we showcase an #ankylosingspondylitis patient profile and market dynamics, such as key comorbidities and evolution of market share. Download here: https://lnkd.in/en2E4ZtT #Pharma #Syndicated #MRX #Insights #ResearchPartnership

Thoughts on this? >> Disc Medicine's rare blood disorder drug meets Phase 2 primary endpoint, misses key secondary >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #biotech #pharma #productmarketing

Thoughts on this? >> Disc Medicine's rare blood disorder drug meets Phase 2 primary endpoint, misses key secondary >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharmaceutical #pharma

Paradigm's 2024 Annual Report has been released. Managing Director Paul Rennie shares: "Paradigm Biopharmaceuticals made significant advancements in FY 2024 with clinical programs in knee osteoarthritis (OA) and mucopolysaccharidosis (MPS). The Company reported outstanding phase 2 data de-risking iPPS for musculoskeletal disorders and engaged in major regulatory discussions with the FDA to advance the 2mg/kg dose for the phase 3 OA program." Key Highlights: - iPPS shows 12-month efficacy - Structural improvements seen at six months - PARA_OA_002 Stage 1 completed Read the full report: https://lnkd.in/gCmVzGp8 #ParadigmBiopharmaceuticals #ASXPAR #AnnualReport #ClinicalTrials #Healthcare #Biotech #AUSBiotech

Thoughts on this? >> European Commission declines CHMP's negative opinion on muscular dystrophy drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #biotech #healthcare #pharma

Thoughts on this? >> FDA raises concerns of 'early deaths' in Abecma and Carvykti multiple myeloma trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #pharmaceutical #biotech

Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps: The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid. #finance #pharmacy #lifesciences